Thursday, July 23, 2020 8:13:22 AM
(SCYX) UP 11% --MC $70 M / Cash $35 M / Low float Stock / NDA filing for first Drug within 4 months / Another 3 Drugs in Phase 3 / Potential Covid 19 Gem = LIFETIME OPP potential next 10 Bagger easily !
Scynexis' lead drug scores in vaginal yeast infection trial
https://endpts.com/scynexis-lead-drug-scores-in-vaginal-yeast-infection-trial/
Ibrexafungerp, if approved, could end up as the only oral alternative to fluconazole approved for acute VVC infections, although Mycovia is testing another therapy, VT-1161, for patients with recurrent VVC, Needham’s Alan Carr wrote in a note, adding that he expects ibrexafungerp to launch in 2021.
“Our data suggest 15% of pts return to their physician because existing treatments are inadequate…physician interest in a new drug is high and we estimate even modest (25%) penetration of the second-line setting generates peak sales (for ibrexafungerp) of over $450M.”
Scynexis' lead drug scores in vaginal yeast infection trial
https://endpts.com/scynexis-lead-drug-scores-in-vaginal-yeast-infection-trial/
Ibrexafungerp, if approved, could end up as the only oral alternative to fluconazole approved for acute VVC infections, although Mycovia is testing another therapy, VT-1161, for patients with recurrent VVC, Needham’s Alan Carr wrote in a note, adding that he expects ibrexafungerp to launch in 2021.
“Our data suggest 15% of pts return to their physician because existing treatments are inadequate…physician interest in a new drug is high and we estimate even modest (25%) penetration of the second-line setting generates peak sales (for ibrexafungerp) of over $450M.”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
